Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize ph...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Creelan, Ben C, Gabrilovich, Dmitry I, Gray, Jhanelle E, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Weber, Jeffrey S, Gibney, Geoffrey T, Markowitz, Joseph, Proksch, Joel W, Reisman, Scott A, McKee, Mark D, Chin, Melanie P, Meyer, Colin J, Antonia, Scott J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2017
Konular:
Clinical Trial Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587199/
https://ncbi.nlm.nih.gov/pubmed/28919776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S136992
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller